Fosun Pharma Acquires Rights to ReNeuron Cell Therapies in $113 Million Deal
publication date: Apr 9, 2019
Shanghai Fosun Pharma in-licensed China rights to two cell therapy programs developed by the UK's ReNeuron Group in a $113 million agreement. Fosun will have rights to develop, manufacture and commercialize ReNeuron's CTX and hRPC cell therapies, both of which are clinical-stage candidates. ReNeuron uses stem cell technologies to develop off-the-shelf stem cell treatments that do not require immunosuppressive drugs. Its CTX cell therapy is aimed at treating the effects of a stroke, and the hRPC cells treat the blindness-causing disease, retinitis pigmentosa. More details....
Stock Symbols: (SHA: 600196; HK: 2196) (AIM: RENE)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.